Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
The Journal of Biological Chemistry|March 22, 2024
Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progressionYe Hyung Lee, A-Rum Yoon, Chae-Ok Yun, et al.
Frontiers in Immunology|May 30, 2024
Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancerA-Rum Yoon, Ao Jiao, JinWoo Hong, et al.
Mathematical Biosciences|December 8, 2020
The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical studyPantea Pooladvand, Chae-Ok Yun, A-Rum Yoon, et al.
International Journal of Cancer|September 21, 2017
Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancerYan Li, JinWoo Hong, Joung-Eun Oh, et al.
The Journal of Gene Medicine|November 19, 2011
RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantationHao Wu, A-Rum Yoon, Feng Li, et al.
Frontiers in Immunology|June 5, 2024
Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapyIn-Wook Kim, A-Rum Yoon, JinWoo Hong, et al.
Nanomedicine (London, England)|June 28, 2016
Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapyDayananda Kasala, A-Rum Yoon, Jinwoo Hong, et al.
Molecular Therapy Oncolytics|April 18, 2022
Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumorsA-Rum Yoon, Cosette Rivera-Cruz, Jeffrey M Gimble, et al.
Biomaterials Science|June 29, 2022
Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasisDayananda Kasala, Soo-Hwan Lee, JinWoo Hong, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 27, 2024
CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancerA-Rum Yoon, Soyeon Lee, Ju Hee Kim, et al.
Pageof 5